Table 1.
Baseline characteristics of trial population
| Characteristic | Liraglutide (n = 23) | Placebo (n = 26) |
|---|---|---|
| Demographics | ||
| Age, years | 60 ± 6 | 59 ± 7 |
| Men | 14 (61) | 15 (58) |
| Diabetes duration, years | 11 ± 6 | 11 ± 7 |
| Diabetic retinopathy, n | 4 (17) | 2 (8) |
| Diabetic nephropathy, n | 2 (9) | 11 (42) |
| Diabetic neuropathy, n | 10 (44) | 7 (27) |
| Diabetic macrovascular complicationsa, n | 2 (9) | 0 (0) |
| Clinical variables | ||
| Weight, kg | 98 ± 14 | 94 ± 13 |
| BMI, kg/m2 | 32.6 ± 4.4 | 31.6 ± 3.4 |
| Waist, cm | 111 ± 10 | 109 ± 9 |
| Hip, cm | 108 ± 8 | 106 ± 7 |
| Waist:hip ratio | 1.03 ± 0.06 | 1.03 ± 0.08 |
| Systolic BP, mmHg | 141 ± 14 | 141 ± 15 |
| Diastolic BP, mmHg | 86 ± 6 | 87 ± 11 |
| Triacylglycerols, mmol/l | 2.2 ± 1.5 | 2.1 ± 1.1 |
| NEFA, mmol/l | 0.7 ± 0.2 | 0.8 ± 0.5 |
| Total cholesterol, mmol/l | 4.8 ± 1.0 | 4.8 ± 1.0 |
| HDL-cholesterol, mmol/l | 1.2 ± 0.2 | 1.3 ± 0.4 |
| LDL-cholesterol, mmol/l | 2.6 ± 0.9 | 2.5 ± 0.9 |
| HbA1c, mmol/mol | 67 ± 12 | 65 ± 10 |
| HbA1c, % | 8.4 ± 1.1 | 8.2 ± 1.0 |
| Adiponectin, mg/l | 5.5 ± 2.4 | 6.5 ± 3.5 |
| AST, U/l | 31 ± 11 | 35 ± 21 |
| ALT, U/l | 15 ± 7 | 13 ± 5 |
| Alkaline phosphatase, U/l | 73 ± 22 | 72 ± 19 |
| GGT, U/l | 38 ± 24 | 34 ± 19 |
| Smoking history | ||
| Never smoked, n | 10 (44) | 8 (31) |
| Current smoker, n | 4 (17) | 5 (19) |
| Ex-smoker, n | 9 (39) | 13 (50) |
| Concomitant drug use | ||
| Metformin dose, g/day | 2.1 ± 0.7 | 2.0 ± 0.5 |
| Sulfonylurea, n | 6 (26) | 8 (31) |
| Insulin, n | 15 (65) | 17 (65) |
| Anti-lipidaemic drug, n | 21 (91) | 19 (73) |
| Anti-hypertensive drug, n | 18 (78) | 20 (77) |
Data are presented as n (%) or mean ± SD
aMacrovascular complications were cerebrovascular or peripheral artery disease and not cardiovascular